We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
-3.63%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
-$232M
(-9.8%)
Cap. Flow
-$62.6M
Cap. Flow
% of AUM
-2.93%
Top 10 Holdings %
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$35M |
| 2 |
Disc Medicine
IRON
|
+$33M |
| 3 |
AnaptysBio
ANAB
|
+$29.5M |
| 4 |
Savara
SVRA
|
+$18.5M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpine Immune Sciences Inc
ALPN
|
+$124M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$52M |
| 3 |
Jade Biosciences
JBIO
|
+$35.6M |
| 4 |
Structure Therapeutics
GPCR
|
+$27M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$22.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.8% |
| 2 | Miscellaneous | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$2.46B
| $235M | 10.99% |
12,226,943
| – | – |
2022 Q4
6 quarters
|
|
2
Mirum Pharmaceuticals
MIRM
$5.35B
| $222M | 10.39% |
6,495,392
| – | – |
2022 Q1
9 quarters
|
|
3
Krystal Biotech
KRYS
$9.77B
| $182M | 8.49% |
988,460
| – | – |
2022 Q1
9 quarters
|
|
4
DELISTED
HilleVax
HLVX
| $154M | 7.18% |
10,617,062
+835,590
| +9% | +$11.5M |
2022 Q2
8 quarters
|
|
5
Phathom Pharmaceuticals
PHAT
$607M
| $104M | 4.87% |
10,109,279
| – | – |
2022 Q1
9 quarters
|
|
6
Rhythm Pharmaceuticals
RYTM
$6.06B
| $97.4M | 4.55% |
2,371,304
+181,125
| +8% | +$7.23M |
2022 Q3
7 quarters
|
|
7
BridgeBio Pharma
BBIO
$13.1B
| $92M | 4.3% |
3,632,604
+217,000
| +6% | +$5.93M |
2023 Q1
5 quarters
|
|
8
Arcutis Biotherapeutics
ARQT
$3.66B
| $81.7M | 3.82% |
8,785,284
| – | – |
2022 Q1
9 quarters
|
|
|
9
Disc Medicine
IRON
$2.17B
| $79.1M | 3.7% |
1,754,834
+969,834
| +124% | +$33M |
2023 Q2
4 quarters
|
|
10
Vaxcyte
PCVX
$10.3B
| $78.5M | 3.67% |
1,039,405
-100,000
| -9% | -$6.81M |
2022 Q1
9 quarters
|
|
11
Edgewise Therapeutics
EWTX
$4.15B
| $67.2M | 3.14% |
3,731,067
+427,500
| +13% | +$7.46M |
2023 Q1
5 quarters
|
|
|
12
AnaptysBio
ANAB
$1.46B
| $54.3M | 2.54% |
2,165,591
+1,265,891
| +141% | +$29.5M |
2022 Q1
9 quarters
|
|
|
VRNA
13
DELISTED
Verona Pharma
VRNA
| $47.9M | 2.24% |
3,314,349
+300,000
| +10% | +$4.38M |
2022 Q3
7 quarters
|
|
14
DELISTED
KalVista Pharmaceuticals
KALV
| $43.4M | 2.03% |
3,687,867
| – | – |
2022 Q1
9 quarters
|
|
15
Tarsus Pharmaceuticals
TARS
$3.32B
| $43.1M | 2.02% |
1,587,527
-200,000
| -11% | -$6.72M |
2022 Q1
9 quarters
|
|
16
Revolution Medicines
RVMD
$40.6B
| $38.7M | 1.81% |
997,455
| – | – |
2023 Q1
5 quarters
|
|
|
17
Erasca
ERAS
$5.2B
| $38.3M | 1.79% |
+16,216,216
| New | +$35M |
2024 Q2
0 quarters
|
|
18
Agios Pharmaceuticals
AGIO
$1.93B
| $37.6M | 1.76% |
871,974
+348,808
| +67% | +$12.6M |
2023 Q3
3 quarters
|
|
19
DELISTED
Soleno Therapeutics
SLNO
| $35.7M | 1.67% |
875,667
| – | – |
2023 Q3
3 quarters
|
|
20
Rocket Pharmaceuticals
RCKT
$259M
| $33.6M | 1.57% |
1,561,230
| – | – |
2023 Q3
3 quarters
|
|
|
21
Savara
SVRA
$974M
| $32.9M | 1.54% |
8,157,385
+4,157,385
| +104% | +$18.5M |
2023 Q3
3 quarters
|
|
22
Oric Pharmaceuticals
ORIC
$1.32B
| $29.3M | 1.37% |
4,142,855
| – | – |
2023 Q2
4 quarters
|
|
23
CG Oncology
CGON
$5.48B
| $24.3M | 1.14% |
770,000
| – | – |
2024 Q1
1 quarter
|
|
24
PepGen
PEPG
$175M
| $24M | 1.12% |
1,502,788
| – | – |
2024 Q1
1 quarter
|
|
25
DELISTED
Merus
MRUS
| $22.1M | 1.03% |
373,100
-373,379
| -50% | -$18.1M |
2022 Q1
9 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q2 2024 Portfolio in Review
As of Q2 2024, Frazier Life Sciences Management held 57 positions worth $2.14B, down 9.8% from $2.37B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Frazier Life Sciences Management's Q2 2024 filing shows 7 new, 13 increased, 4 reduced and 8 closed positions. Its largest new stake was Erasca: 16,216,216 shares worth $38.3M. The largest sale was Alpine Immune Sciences Inc, an estimated $124M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q2 2024 buy was Erasca: 16,216,216 shares worth $38.3M.
- Frazier Life Sciences Management added most to Disc Medicine in Q2 2024, an estimated $33M increase.
- Frazier Life Sciences Management's biggest Q2 2024 reduction was Merus, cutting an estimated $18.1M.
- Frazier Life Sciences Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $124M.
- Frazier Life Sciences Management's ten largest holdings make up 62% of its $2.14B portfolio in Q2 2024.
- Frazier Life Sciences Management opened 7 new positions and closed 8 in Q2 2024.
- Frazier Life Sciences Management's portfolio value fell 9.8% quarter-over-quarter to $2.14B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.